Presentation (CTI)

OBJECTIVES: The European Commission has released its first Joint Clinical Assessment (JCA) report, a major milestone for the European Union (EU) Health Technology Assessment (HTA) framework. The evaluation of tovorafenib for paediatric low-grade glioma (LGG) is the first real-world example of how comparative clinical evidence will be assessed at the EU level. This study aims to analyze the key lessons emerging from the first EU JCA and their implications for future evidence generation and EU HTA submission strategies.
METHODS: The JCA report for tovorafenib, published by the European HTA bodies through the EU HTA framework, was reviewed to assess evidence requirements, comparator selection, indirect treatment comparisons, patient-reported outcomes, and implications for future submissions.
RESULTS: The critical review of the report revealed the assessment highlighted substantial limitations in the evidence base analysed. No direct comparative data was available. Only one of eight PICOs could be evaluated using an unanchored matching-adjusted indirect comparison (MAIC), which highlighted the importance of comparative evidence under EU HTA. The pivotal single arm study, FIREFLY-1 limited conclusions on relative effectiveness, while concerns about residual confounding, limited covariate adjustment, poor population overlap, reduced sample size, and inconsistent outcome definitions created substantial uncertainty. In addition, patient-centred outcomes, such as health-related quality of life and symptom measures, were largely unavailable, limiting the assessment of patient-centered benefit. The assessment underscores the need to align evidence strategies with both regulatory and HTA requirements, with EU HTA success increasingly dependent on comparative, PICO-aligned, and patient-centred evidence rather than regulatory efficacy data alone.
CONCLUSIONS: The first EU JCA signals a shift toward comparative, PICO aligned, and patient-centred evidence for HTA success. Early integration of HTA requirements into clinical development will be essential for future EU market access.